Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Liabilities and Shareholders Equity (2018 - 2025)

Silence Therapeutics' Liabilities and Shareholders Equity history spans 8 years, with the latest figure at $131.4 million for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 35.13% to $131.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $628.8 million, a 30.71% decrease, with the full-year FY2025 number at $131.4 million, down 35.13% from a year prior.
  • Liabilities and Shareholders Equity hit $131.4 million in Q4 2025 for Silence Therapeutics, down from $146.8 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for SLN hit a ceiling of $246.6 million in Q1 2024 and a floor of $105.0 million in Q2 2022.
  • Historically, Liabilities and Shareholders Equity has averaged $154.1 million across 5 years, with a median of $136.1 million in 2021.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 115.03% in 2024 and later tumbled 35.13% in 2025.
  • Tracing SLN's Liabilities and Shareholders Equity over 5 years: stood at $129.7 million in 2021, then dropped by 2.76% to $126.1 million in 2022, then decreased by 5.27% to $119.4 million in 2023, then skyrocketed by 69.64% to $202.6 million in 2024, then tumbled by 35.13% to $131.4 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for SLN at $131.4 million in Q4 2025, $146.8 million in Q3 2025, and $165.2 million in Q2 2025.